At ASH 2025, Kite unveiled data that underscores a clear message: Yescarta® is reshaping expectations for relapsed or refractory large B-cell lymphoma.
By combining long-term results from ZUMA-7 and ALYCANTE, researchers showed that Yescarta delivers remarkably consistent survival and response rates—including for patients once considered too high-risk for transplant or aggressive chemotherapy.
Breakthrough results at two years:
• Nearly 65% survival — tripling historical outcomes
• Strong, lasting disease control across both studies
• Over 55% complete responses within three months
• More than 60% of responders staying in response for a year
Safety remained stable and predictable, with comparable rates of serious side effects in both trials.
Patients also saw meaningful quality-of-life improvements that strengthened over time.
Experts emphasize that these findings reinforce Yescarta’s role as a therapy with curative intent and a transformative option for patients with aggressive lymphoma.